ID   FT33-shp53-R24C
AC   CVCL_RK66
SY   FT33; iFTSEC33
DR   ABM; T0609
DR   GEO; GSM1663024
DR   GEO; GSM1663025
DR   GEO; GSM1663026
DR   GEO; GSM1663027
DR   GEO; GSM1663028
DR   GEO; GSM1663029
DR   GEO; GSM1663030
DR   GEO; GSM1663031
DR   Wikidata; Q54835216
RX   PubMed=21502498;
RX   PubMed=22936217;
RX   PubMed=25804953;
RX   PubMed=30487138;
CC   Knockout cell: Method=shRNA knockdown; HGNC; HGNC:11998; TP53.
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:1773; CDK4 (Note=With p.Arg24Cys).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:11730; TERT.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; ChIP-seq; H3K4me1.
CC   Discontinued: ABM; T0609; true.
CC   Derived from site: In situ; Fallopian tube; UBERON=UBERON_0003889.
CC   Cell type: Fallopian tube secretory epithelial cell; CL=CL_4030006.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Telomerase immortalized cell line
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 12
//
RX   PubMed=21502498; DOI=10.1073/pnas.1017300108; PMCID=PMC3088633;
RA   Karst A.M., Levanon K., Drapkin R.I.;
RT   "Modeling high-grade serous ovarian carcinogenesis from the fallopian
RT   tube.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:7547-7552(2011).
//
RX   PubMed=22936217; DOI=10.1038/nprot.2012.097; PMCID=PMC7433321;
RA   Karst A.M., Drapkin R.I.;
RT   "Primary culture and immortalization of human fallopian tube secretory
RT   epithelial cells.";
RL   Nat. Protoc. 7:1755-1764(2012).
//
RX   PubMed=25804953; DOI=10.1093/hmg/ddv101; PMCID=PMC4459387;
RA   Coetzee S.G., Shen H.C., Hazelett D.J., Lawrenson K.,
RA   Kuchenbaecker K., Tyrer J.P., Rhie S.K., Levanon K., Karst A.M.,
RA   Drapkin R.I., Ramus S.J., Couch F.J., Offit K., Chenevix-Trench G.,
RA   Monteiro A.N.A., Antoniou A., Freedman M.L., Coetzee G.A.,
RA   Pharoah P.D.P., Noushmehr H., Gayther S.A.;
RG   Consortium of Investigators of Modifiers of BRCA1/2;
RG   Ovarian Cancer Association Consortium;
RT   "Cell-type-specific enrichment of risk-associated regulatory elements
RT   at ovarian cancer susceptibility loci.";
RL   Hum. Mol. Genet. 24:3595-3607(2015).
//
RX   PubMed=30487138; DOI=10.1158/0008-5472.CAN-17-3864; PMCID=PMC6359979;
RA   Buckley M.A., Woods N.T., Tyrer J.P., Mendoza-Fandino G.,
RA   Lawrenson K., Hazelett D.J., Najafabadi H.S., Gjyshi A.,
RA   Carvalho R.S., Lyra P.C. Jr., Coetzee S.G., Shen H.C., Yang A.W.,
RA   Earp M.A., Yoder S.J., Risch H., Chenevix-Trench G., Ramus S.J.,
RA   Phelan C.M., Coetzee G.A., Noushmehr H., Hughes T.R., Sellers T.A.,
RA   Goode E.L., Pharoah P.D.P., Gayther S.A., Monteiro A.N.A.;
RT   "Functional analysis and fine mapping of the 9p22.2 ovarian cancer
RT   susceptibility locus.";
RL   Cancer Res. 79:467-481(2019).
//